SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
London Stock Exchange
Börse London Stock Exchange
ISIN GB0009252882
  • Glaxosmithkline
    Börse London Stock Exchange
    ISIN GB0009252882
    Symbol GSK
  • Glaxosmithkline
    Börse Börse Frankfurt
    ISIN GB0009252882 WKN: 940561
    Symbol GS7
    EUR
  • Glaxosmithkline
    Börse Börse Berlin
    Symbol GS7A
    EUR
  • GLAXOSMITHKLINE PLC-SPON ADR
    Börse Börse Frankfurt
    Symbol GS7A
    EUR
  • Glaxosmithkline
    Börse Börse Stuttgart
    Symbol GS7A
    EUR
  • Glaxosmithkline
    Börse Börse München
    Symbol GS7A
    EUR
  • Glaxosmithkline
    Börse Gettex System der Börse München
    Symbol GS7A
    EUR
  • GLAXOSMITHKLINE PLC
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol GS7
    EUR
  • GLAXOSMITHKLINE PLC
    Börse Börse Berlin
    Symbol GS7
    EUR
  • GLAXOSMITHKLINE PLC
    Börse Quotrix System der Börse Düsseldorf
    Symbol GS7
    EUR
  • GLAXOSMITHKLINE PLC
    Börse Börse Hamburg
    Symbol GS7
    EUR
  • GLAXOSMITHKLINE PLC
    Börse Börse Düsseldorf
    Symbol GS7
    EUR
  • GLAXOSMITHKLINE PLC
    Börse Börse München
    Symbol GS7
    EUR
  • GLAXOSMITHKLINE PLC
    Börse Börse Stuttgart
    Symbol GS7
    EUR
  • GLAXOSMITHKLINE PLC
    Börse Gettex System der Börse München
    Symbol GS7
    EUR
  • Glaxosmithkline
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol GS7A
    EUR
  • Glaxosmithkline
    Börse Börse Hamburg
    Symbol GS7A
    EUR
  • Glaxosmithkline
    Börse Quotrix System der Börse Düsseldorf
    Symbol GS7A
    EUR
  • Glaxosmithkline
    Börse Börse Düsseldorf
    Symbol GS7A
    EUR
  • Glaxosmithkline
    Börse NYSE New York Stock Exchange
    ISIN GB0009252882 WKN: 940561
    Symbol GSK
  • Glaxosmithkline
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    Symbol GSK.LN
    USD
  • GlaxoSmithKline PLC ADR
    Börse NYSE New York Stock Exchange
    ISIN US37733W1053 WKN: 940610
    Symbol GSK
  • GLAXOSMITHKLINE PHARMACEUTICAL
    Börse BSE
    INR
  • Glaxosmithkline
    Börse Freiverkehr OTC
    USD
  • Symbol GS7
ISIN GB0009252882
Symbol GSK
Börse London Stock Exchange Zeitzone: America/New_York
Marktkapitalisierung 85.886.954.672 (+- 9%)

Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:

93.879.525.376 oder 82.199.000.000 oder 81.582.338.640

Mitarbeiter 92.081 (+- 2%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

94.066 oder 90.096 Mitarbeiter

Anzahl Aktien 5.017.364.000
KGV 15.97 (+- 18%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

13.04 oder 18.9

EBITDA 9.715.999.744
PEGRatio 4.5095
Buchwert 5.942

Zahlte zuletzt am 20.05.2021 eine Dividende von 19  . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht

Glaxosmithkline läuft ähnlich wie der DAX (1.29 %) vom 05.07.2021 bis 10.09.2021

Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 1478,4 GBp +0,73% 

Analystenmeinungen

Übersicht

Aktionärsstruktur der GlaxoSmithKline plc

238 News & Informationen zur Glaxosmithkline Aktie

  • Global Pediatric Vaccine Market Research Report 2021: Market is Expected to Reach $49.9 Billion in 2025 - Long-term Forecast to 2030
    prnewswire.com

    Global Pediatric Vaccine Market Research Report 2021: Market is Expected to Reach $49.9 Billion in 2025 – Long-term Forecast to 2030

    /PRNewswire/ — The

  • Drug Delivery Devices Global Markets Report 2021: COVID-19 Impacts, Implications And Growth Factors To 2030
    thestreet.com

    Drug Delivery Devices Global Markets Report 2021: COVID-19 Impacts, Implications And Growth Factors To 2030

    DUBLIN, Aug. 6, 2021 /PRNewswire/ — The “Drug Delivery Devices Global Market Report 2021: COVID-19 Implications and Growth to 2030” report has been added to

  • 10 Biotech Penny Stocks to Buy According to Reddit
    insidermonkey.com

    10 Biotech Penny Stocks to Buy According to Reddit

    In this article, we discuss the 10 biotech penny stocks to buy according to Reddit.

  • Global Depression Treatment Market (2020 to 2026) - Featuring Allergen, Bausch Health Companies and Lief Therapeutics Among Others
    prnewswire.com

    Global Depression Treatment Market (2020 to 2026) – Featuring Allergen, Bausch Health Companies and Lief Therapeutics Among Others

    /PRNewswire/ — The

  • Global Cancer Therapies Market to Reach $204.2 Billion by 2024
    prnewswire.com

    Global Cancer Therapies Market to Reach $204.2 Billion by 2024

    /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…

  • PlantFuel Solidifies Its Executive Leadership Team, Names New CEO, President And Chairman Of The Board
    thestreet.com

    PlantFuel Solidifies Its Executive Leadership Team, Names New CEO, President And Chairman Of The Board

    MISSISSAUGA, ON, Aug. 3, 2021 /PRNewswire/ — PlantFuel Life  Inc.(CSE: FUEL) (OTC: BLLXF) (FSE: BR1B) ( “PlantFuel” or the “Company”)has officially named Brad

  • Sanofi Snaps Up mRNA Specialist for $3.2 Billion Amid Vaccine Success
    online.wsj.com

    Sanofi Snaps Up mRNA Specialist for $3.2 Billion Amid Vaccine Success

    French healthcare company Sanofi agreed to acquire Translate Bio, a big vote of confidence that the new technology underpinning two successful Covid-19 vaccines holds promise beyond the pandemic.

  • 2 of the best UK stocks to buy
    fool.co.uk

    2 of the best UK stocks to buy

    These two top UK stocks have caught my attention in early August trading. Here's why I'd buy them for my shares portfolio.

  • Barron's Latest Picks And Pans: American Express, GE, GlaxoSmithKline, Intel And More
    markets.businessinsider.com

    Barron's Latest Picks And Pans: American Express, GE, GlaxoSmithKline, Intel And More

    This weekend's Barron's offers investors an overlooked way to play the coming infrastructure surge. Other featured articles discuss how t…

  • 3 High Ebitda Margin Ratio Stock Picks
    gurufocus.com

    3 High Ebitda Margin Ratio Stock Picks

    GuruFocus Article or News written by Alberto Abaterusso and the topic is about: These businesses appear to be in a good shape from a financial standpoint

  • Insights on the Targeted Therapeutics Global Market to 2031 - Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others
    prnewswire.com

    Insights on the Targeted Therapeutics Global Market to 2031 – Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others

    /PRNewswire/ — The “Targeted Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031” report has been added to…

  • Insights on the Targeted Therapeutics Global Market to 2031 - Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others
    markets.businessinsider.com

    Insights on the Targeted Therapeutics Global Market to 2031 – Featuring Sanofi, Takeda Pharmaceutical and Novartis Among Others

    DUBLIN, July 30, 2021 /PRNewswire/ — The 'Targeted Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 202…

  • GSK : FDA Approves Mepolizumab For Use In Adults With Chronic Rhinosinusitis With Nasal Polyps
    markets.businessinsider.com

    GSK : FDA Approves Mepolizumab For Use In Adults With Chronic Rhinosinusitis With Nasal Polyps

    (RTTNews) – GlaxoSmithKline plc (GSK, GSK.L) said that the US Food and Drug Administration has approved Nucala or mepolizumab, a monoclonal antibo…

  • Bestinfond's Top 2nd-Quarter Trades
    gurufocus.com

    Bestinfond's Top 2nd-Quarter Trades

    GuruFocus Article or News written by Margaret Moran and the topic is about: Spanish fund invests in banking group, sells industrials

  • GSK Announces FDA Approval For Nucala (mepolizumab) For Use In Adults With Chronic Rhinosinusitis With Nasal Polyps
    thestreet.com

    GSK Announces FDA Approval For Nucala (mepolizumab) For Use In Adults With Chronic Rhinosinusitis With Nasal Polyps

    GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets

  • Keating Investment Counselors Inc Buys GlaxoSmithKline PLC, TotalEnergies SE, Kirkland Lake Gold, Sells Cal-Maine Foods Inc, Honeywell...
    gurufocus.com

    Keating Investment Counselors Inc Buys GlaxoSmithKline PLC, TotalEnergies SE, Kirkland Lake Gold, Sells Cal-Maine Foods Inc, Honeywell International Inc, Emerson Electric Co

    GuruFocus Article or News written by insider and the topic is about:

  • Essex Savings Bank Buys Verisk Analytics Inc, BlackRock Inc, Citigroup Inc, Sells iShares National Muni Bond ETF, iShares Gold Trust,...
    gurufocus.com

    Essex Savings Bank Buys Verisk Analytics Inc, BlackRock Inc, Citigroup Inc, Sells iShares National Muni Bond ETF, iShares Gold Trust, GlaxoSmithKline PLC

    GuruFocus Article or News written by insider and the topic is about:

  • Bestinfond Buys NatWest Group PLC, Holcim, Laboratorios Farmaceuticos Rovi SA, Sells Befesa SA, Ashtead Group PLC, FLSmidth. A/S
    gurufocus.com

    Bestinfond Buys NatWest Group PLC, Holcim, Laboratorios Farmaceuticos Rovi SA, Sells Befesa SA, Ashtead Group PLC, FLSmidth. A/S

    GuruFocus Article or News written by insider and the topic is about:

  • Monoclonal Antibodies Market to Reach $390.58 Bn, Globally at 10.2% CAGR by 2030: Says AMR
    prnewswire.com

    Monoclonal Antibodies Market to Reach $390.58 Bn, Globally at 10.2% CAGR by 2030: Says AMR

    /PRNewswire/ — According to the report the, global monoclonal antibodies market was pegged at $146.64 billion in 2020 and is estimated to reach $390.58…

  • Global Anti-epileptic Drugs Market to surpass US$ 7,344.9 Million by 2028, Says Coherent Market Insights (CMI)
    globenewswire.com

    Global Anti-epileptic Drugs Market to surpass US$ 7,344.9 Million by 2028, Says Coherent Market Insights (CMI)

    SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) — Global Anti-epileptic Drugs Market to surpass US$ 7,344.9 Million by 2028, Says Coherent Market Insights (CMI)…

  • LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®
    markets.businessinsider.com

    LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

    PHILADELPHIA, July 29, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercia…

  • GlaxoSmithKline : Q2 2021 results transcript PDF - 168.2KB
    marketscreener.com

    GlaxoSmithKline : Q2 2021 results transcript PDF – 168.2KB

    GlaxoSmithKline plc

    Q2 2021 Results

    Presentation to Analysts

    Wednesday, 28 July 2021

    Iain Mackay… | July 29, 2021

  • Global Nanobiotechnology Applications And Markets 2021-2026: Molecular Diagnostic, Therapeutics, & Biopharmaceutical Application
    thestreet.com

    Global Nanobiotechnology Applications And Markets 2021-2026: Molecular Diagnostic, Therapeutics, & Biopharmaceutical Application

    DUBLIN, July 27, 2021 /PRNewswire/ — The

  • WOCHENVORSCHAU: Termine bis 10. August 2021
    finanzen.net

    WOCHENVORSCHAU: Termine bis 10. August 2021

    WOCHENVORSCHAU: Termine bis 10. August 2021 | Nachricht | finanzen.net

  • Global Polycythemia Vera Therapeutics Market to Surpass US$ 1,516.5 Million by 2028, Says Coherent Market Insights (CMI)
    globenewswire.com

    Global Polycythemia Vera Therapeutics Market to Surpass US$ 1,516.5 Million by 2028, Says Coherent Market Insights (CMI)

    SEATTLE, July 27, 2021 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global polycythemia vera therapeutics market is estimated to be…

  • Global $9.5 Billion Influenza Vaccines Market to 2027
    prnewswire.com

    Global $9.5 Billion Influenza Vaccines Market to 2027

    /PRNewswire/ — The “Global Influenza Vaccines Market, Persons Vaccinated, Impact of COVID-19, Company Analysis, Size, Share, Growth, Trends, Major Deals -…

  • GlaxoSmithKline ( '') (Form 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
    marketscreener.com

    GlaxoSmithKline ( '') (Form 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)

    GlaxoSmithKline plc

    Transaction notification

    1.

    … | July 26, 2021

  • WOCHENVORSCHAU: Termine bis 09. August 2021
    finanzen.net

    WOCHENVORSCHAU: Termine bis 09. August 2021

    WOCHENVORSCHAU: Termine bis 09. August 2021 | Nachricht | finanzen.net

  • GlaxoSmithKline Gets FDA Approval for Shingles Vaccine
    marketscreener.com

    GlaxoSmithKline Gets FDA Approval for Shingles Vaccine

    By Chris Wack

    GlaxoSmithKline Plc said the U.S. Food and Drug Administration has approved Shingrix for the prevention of shingles in adults aged 18 years and older who are or will be at… | July 26, 2021

  • GlaxoSmithKline : Shingrix approved in the US for prevention of shingles in immunocompromised adults
    marketscreener.com

    GlaxoSmithKline : Shingrix approved in the US for prevention of shingles in immunocompromised adults

    For media and investors only

    Issued: Philadelphia, London

    GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Shingrix … | July 26, 2021

  • Shingrix approved in the US for prevention of shingles in immunocompromised adults
    prnewswire.com

    Shingrix approved in the US for prevention of shingles in immunocompromised adults

    /PRNewswire/ — GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant,…

  • Shingrix approved in the US for prevention of shingles in immunocompromised adults
    markets.businessinsider.com

    Shingrix approved in the US for prevention of shingles in immunocompromised adults

    LONDON and PHILADELPHIA, July 26, 2021 /PRNewswire/ — GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has appr…

  • Community Financial Services Group, LLC Buys The Toronto-Dominion Bank, Honeywell International Inc, Starbucks Corp, Sells iShares Russell...
    gurufocus.com

    Community Financial Services Group, LLC Buys The Toronto-Dominion Bank, Honeywell International Inc, Starbucks Corp, Sells iShares Russell 1000 Growth ETF, Royal Dutch Shell PLC, GlaxoSmithKline PLC

    GuruFocus Article or News written by insider and the topic is about:

  • Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period - by PMI
    globenewswire.com

    Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period – by PMI

    Covina, CA, July 22, 2021 (GLOBE NEWSWIRE) — The Global Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$…

  • Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period - by PMI
    globenewswire.com

    Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period – by PMI

    Covina, CA, July 22, 2021 (GLOBE NEWSWIRE) — The Global Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$…

  • Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period - by PMI
    globenewswire.com

    Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period – by PMI

    Covina, CA, July 22, 2021 (GLOBE NEWSWIRE) — The Global Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$…

  • Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period - by PMI
    globenewswire.com

    Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period – by PMI

    Covina, CA, July 22, 2021 (GLOBE NEWSWIRE) — The Global Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$…

  • Outlook On The Nutritional Supplements Global Market To 2027 - Trend Forecasts And Growth Opportunities
    thestreet.com

    Outlook On The Nutritional Supplements Global Market To 2027 – Trend Forecasts And Growth Opportunities

    DUBLIN, July 22, 2021 /PRNewswire/ — The “Global Nutritional Supplements Market 2020-2027 by Ingredient, Product Form, Category, Application, End User,

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Portrait der Glaxosmithkline Aktie

Das Unternehmen GlaxoSmithKline plc aus Großbritannien beschäftigt 92.081 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie & Pharmazeutika, Pharma tätig.

Die Glaxosmithkline Aktie hat inklusive der Dividendenausschüttungen seit dem 05.07.2021 eine Gesamtrendite von 0% erwirtschaftet

Das Unternehmen GlaxoSmithKline plc ist in mehr als 78 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter iShares STOXX Europe Select Dividend 30  UCITS  ETF (DE) gewichtet Glaxosmithkline mit 6,17% im ETF.

Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Glaxosmithkline Anleihen auf einen Blick.

Entdecke die 6 ETFs in denen GlaxoSmithKline plc am höchsten gewichtet ist Insgesamt in 78 ETFs enthalten

Dir gefallen die Informationen zu Glaxosmithkline?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Glaxosmithkline?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic

Dir gefallen die Informationen zu Glaxosmithkline?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero

Dir gefallen die Informationen zu Glaxosmithkline?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba